PNAS:痴呆?帕金森?说不定是大脑缺了这个蛋白!

2019-12-06 转网 转化医学网

万事知其然才能知其所以然,但这些疾病的发病机制至今众说纷纭,有效的治疗方法扑朔迷离,研究长期桎梏于困境。近日,洛克菲勒大学的研究人员发现了造成神经退行性疾病患者大脑中异常蛋白斑块的罪魁祸首——缺失PI31蛋白。他们指出,这种蛋白的缺失可引发两大问题,不仅使异常蛋白的分解受损,还阻碍了神经元间的蛋白酶体交流,进而导致局部蛋白异常淤积,AD的β淀粉样蛋白和PD的α-突触核蛋白的大量聚集正是来源于此。泛

万事知其然才能知其所以然,但这些疾病的发病机制至今众说纷纭,有效的治疗方法扑朔迷离,研究长期桎梏于困境。近日,洛克菲勒大学的研究人员发现了造成神经退行性疾病患者大脑中异常蛋白斑块的罪魁祸首——

缺失PI31蛋白。他们指出,这种蛋白的缺失可引发两大问题,不仅使异常蛋白的分解受损,还阻碍了神经元间的蛋白酶体交流,进而导致局部蛋白异常淤积,AD的β淀粉样蛋白和PD的α-突触核蛋白的大量聚集正是来源于此。

泛素-蛋白酶体系统(UPS)崩解,异常蛋白淤积

通过降解来控制蛋白质半衰期已成为维持细胞稳态的主要细胞机制。人类细胞中主要存在两类蛋白质降解的途径,一是溶酶体降解途径,二是UPS。UPS是真核细胞内ATP依赖的蛋白降解系统,可高度选择并高效降解细胞内的蛋白质。UPS中的蛋白酶体由多个蛋白质亚基组成,在短期细胞蛋白质的降解中起重要作用。UPS还参与了信号转导和各种细胞功能的调节,其功能障碍或失调可能是某些神经系统疾病的重要致病机制。

PI31蛋白是一种与蛋白酶体装配息息相关的蛋白质,可促进26S蛋白酶体的组装。研究人员发现,PI31的失活可导致蛋白酶体活性降低,同时减少人泛素蛋白(Ub)的降解,神经元对该反应特别敏感,因为神经蛋白中Ub占有极大比例,尤其是因基因突变产生的β淀粉样蛋白和α-突触核蛋白。他们证实,PI31活性是维持神经元蛋白质稳态的不可或缺的分子。一旦PI31失活,UPS的蛋白酶体组装受制,UPS崩解,使得异常蛋白无法分解,这些蛋白的大量淤积正是损害神经元,引发神经退行性疾病的重要原因。

神经元蛋白酶体运输受制,蛋白质稳态破坏

蛋白酶体是在神经元细胞体中制成的,需要长距离运输才能到达神经末梢,而且神经元对与其他细胞连接,因此,在某些情况下,蛋白酶体的转运行程可超过一米。研究人员发现,PI31蛋白正是神经元蛋白酶体运输的衔接子,保证了蛋白酶体在神经元间的运动。一旦PI31被破坏,这些运动都会停止。若蛋白酶体无法到达关键的通讯枢纽,细胞就会陷入混乱。

PI31蛋白失活导致严重的运动缺陷和脊髓中的蛋白毒性应激

PI31蛋白失活导致轴突、树突变性

他们指出,PI31蛋白的功能性失活引发神经蛋白运输异常,导致突触蛋白的稳态和结构、运动功能均受到严重破坏,使得突触间信息交流成了“无米之炊”,这就会引发轴突树突变性,同时产生蛋白应激毒性。随着年龄的增长,神经元突触结构和功能的退化会越来越严重,最终可导致神经元的丧失。而那些被“拦截”下来的蛋白质可与其他蛋白伴侣相结合并互相聚集,变成了对神经元有极大毒性作用的有害蛋白团,进一步加速了神经元的老化与死亡。其中脊髓运动神经元(MNs)和小脑Purkinje细胞(PCs)受PI31蛋白失活的影响最为严重,可导致严重的运动缺陷和脊髓中的蛋白毒性应激,也可引发进行性肌肉失神经和萎缩,而这两种神经元的丧失也是AD和PD的核心表现之一。

这项研究确立了PI31蛋白在神经蛋白降解、运输中的重要作用,明确了其在维持神经元结构、电路和功能中的核心地位,同时指出PI31相关变异与神经退行性疾病的关系,为相关疾病的诊疗提供了新型靶点,也为疾病机制的研究提供了新思路。我们也需要更多时间和实验对这些结论进行更为深入的了解,才能让这些成果真正惠及患者,成为众人福音。

参考文献:

Adi Minis,et al.The proteasome regulator PI31 is required for protein homeostasis, synapse maintenance, and neuronal survival in mice.PNAS December 3, 2019 116 (49) 24639-24650.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2020-07-11 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2019-12-06 junJUN

    老年人痴呆何药可用??

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2019-12-06 14794e5bm67(暂无昵称)

    非常感谢好的研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2019-12-06 14794e5bm67(暂无昵称)

    非常感谢好的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2019-12-06 14794e5bm67(暂无昵称)

    非常感谢好的研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2019-12-06 14794e5bm67(暂无昵称)

    非常感谢好的研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1856369, encodeId=f11118563690a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 11 01:48:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048580, encodeId=3cd3104858067, content=老年人痴呆何药可用??, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Dec 06 13:48:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376629, encodeId=5fcf3e6629d8, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:48 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376628, encodeId=65733e6628d9, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:45 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376627, encodeId=c5e93e66278b, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:43 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376626, encodeId=37d43e662665, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:40 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376625, encodeId=6ae73e662564, content=非常感谢好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Dec 06 11:42:37 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2019-12-06 14794e5bm67(暂无昵称)

    非常感谢好的研究

    0

相关资讯

Front Mol Neurosci:撇开兴奋剂不谈,如何发挥Epo的神经保护作用?

Epo可用来治疗神经退行性疾病,如阿尔茨海默病和帕金森病,或减少中风后的损伤。然而,临床研究发现了严重的副作用,这可能是由于Epo能够刺激红细胞生成。如何将Epo的这两种作用区分开?德国哥廷根大学的研究人员展开了深入研究。

NEJM:橄榄球运动员的神经退行性疾病死亡风险增加

在这项回顾性流行病学分析中,前苏格兰职业橄榄球运动员的神经退行性疾病死亡率高于对照组,其他常见疾病死亡率低于对照组

PNAS:王晓东团队发现新化合物,保护线粒体,拯救神经疾病!

近日,发表在《PNAS》上的一篇研究中,北京生命科学研究所所长王晓东团队发现的一种蛋白质有助于逆转实验动物中风样神经损伤,该研究有朝一日可能会将人类从痛苦的神经疾病中解救出来。

Nat Genet:这个基因竟与四种罕见神经退行性疾病都有关

神经退行性疾病一直是医学研究难以攻克的一大疾病,像是阿尔茨海默症、帕金森、癫痫、亨廷顿病等都是我们所熟悉的神经退行性疾病。当然,对于一些罕见的神经退行性疾病科学家也没有放弃。同一种疾病可能是由于不同的基因突变导致的,这就使得许多遗传性疾病治疗变得复杂。如果能够找到其中的共同点,或将为治疗带来新方法。

Nature:复旦大学鲁伯埙、丁澦、费义艳团队合作研发亨廷顿病潜在新药

亨廷顿病(或称亨廷顿舞蹈症)位列四大神经退行性疾病之一,临床表现为不自主的舞蹈样动作、认知障碍、精神异常等症状。由于引起该病的变异亨廷顿蛋白(mHTT)生化活性未知,无法靶向,传统依靠阻断剂以阻断致病蛋白活性的方法并不适用。

PNAS:王晓东团队发现新化合物:保护线粒体,拯救神经疾病!

已知线粒体损伤和细胞死亡与多种神经退行性疾病有关,如帕金森症和中风。